Effect of Omega-3 supplementation on endothelial function & quality of life in hemodialysis patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201309242417N13

Enrollment

Registered

2013-10-29

Start date

2013-10-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End Stage Renal Disease. End Stage Renal Disease

Interventions

Intervention 1: Cap Omega-3 1000mg 3capsule per day for 6 months manufactured by Zahravi company. Intervention 2: Cap placebo for 6 months manufactured by Zahravi company.

Treatment - Drugs

Placebo

Cap Omega-3 1000mg 3capsule per day for 6 months manufactured by Zahravi company

Cap placebo for 6 months manufactured by Zahravi company

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1)at least 18 years old. 2)hemodialysis for at least 3 months. 3)consent for cooperation 4) without usage of omega-3 during past 3 months Exclusion criteria: 1)history of steatorrhea. 2) malignancy. 3) abnormal coagulation profile. 4)need for anticoagulation therapy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Serum ICAM level. Timepoint: at begining and after 6 months. Method of measurement: ELISA kit, µg/mL.;Serum VCAM level. Timepoint: at begining and after 6 months. Method of measurement: ELISA kit, µg/mL.;Quality of life of hemodialysis patients. Timepoint: at begining and after 6 months. Method of measurement: questioneer.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Firouzeh Moeinzadeh

Isfahan University of Medical Sciences

moinzade@resident.mui.ac.ir+98 31 1625 5555

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026